UK NICE · April 29, 2026

NICE recommendation: rozanolixizumab for uncontrolled generalised myasthenia gravis

Original title: First NICE recommended treatment for uncontrolled generalised myasthenia gravis

NICE recommends rozanolixizumab for adults with generalised myasthenia gravis uncontrolled by existing treatments.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement UK Pharmaceuticals

We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis (gMG) whose symptoms are not controlled by existing treatments.

Read the official source ↗

Published by UK NICE. HealthSignal links to the original document; the summary above is extracted from the source text.